CVS Health (NYSE: CVS) recently received a number of ratings updates from brokerages and research firms:
- 11/9/2026 – CVS Health was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
- 11/6/2026 – CVS Health was given a new $103.00 price target by Raymond James Financial.
- 11/5/2026 – CVS Health had its price target lowered by UBS Group from $118.00 to $107.00. They now have a “buy” rating on the stock.
- 11/5/2026 – CVS Health had its price target lowered by Leerink Partners from $112.00 to $104.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – CVS Health had its price target lowered by Barclays from $108.00 to $107.00. They now have an “overweight” rating on the stock.
- 11/4/2026 – CVS Health had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $103.00 price target on the stock.
- 11/4/2026 – CVS Health had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $120.00 price target on the stock.
- 11/4/2026 – CVS Health was given a new $110.00 price target by UBS Group.
- 11/4/2026 – CVS Health had its “buy” rating reaffirmed by TD Cowen.
- 11/4/2026 – CVS Health had its “outperform” rating reaffirmed by Evercore.
- 10/19/2026 – CVS Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 10/12/2026 – CVS Health had its price target lowered by Leerink Partners from $119.00 to $112.00. They now have an “outperform” rating on the stock.
- 10/11/2026 – CVS Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 10/9/2026 – CVS Health was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
- 10/9/2026 – CVS Health had its “neutral” rating reaffirmed by Cantor Fitzgerald.
- 10/3/2026 – CVS Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 10/1/2026 – CVS Health had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 9/22/2026 – CVS Health had its “buy” rating reaffirmed by UBS Group.
- 9/20/2026 – CVS Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 9/12/2026 – CVS Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
CVS Health Price Performance
Shares of CVS Health stock traded down $1.42 on Wednesday, hitting $87.59. The company’s stock had a trading volume of 2,014,839 shares, compared to its average volume of 8,561,148. The firm has a fifty day moving average price of $90.12 and a 200-day moving average price of $88.94. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a market capitalization of $112.06 billion, a price-to-earnings ratio of 10.20, a price-to-earnings-growth ratio of 0.74 and a beta of 0.58. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85.
CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.65 by $0.44. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.60 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 8.25 earnings per share for the current fiscal year.
CVS Health Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date was Thursday, October 22nd. CVS Health’s dividend payout ratio is 30.97%.
Insider Buying and Selling
In related news, EVP Prem Shah acquired 23,855 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were acquired at an average cost of $83.89 per share, for a total transaction of $2,001,195.95. Following the acquisition, the executive vice president directly owned 88,516 shares in the company, valued at approximately $7,425,607.24. The trade was a 36.89% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.85% of the company’s stock.
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Featured Articles
- Five stocks we like better than CVS Health
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
